EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSVPAG00000004295
Gene Symbol: MAP3K1
3 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSVPAG00000012002
Gene Symbol: MAP3K13
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSVPAG00000003929
Gene Symbol: MAP3K5
1 Cross references
203 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSVPAG00000000657
Gene Symbol: MAOA
1 Cross references
146 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSVPAG00000000658
Gene Symbol: MAOB
1 Cross references
330 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSVPAG00000012011
Gene Symbol: MLNR
1 Cross references
165 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSVPAG00000005585
Gene Symbol: NPR2
1 Cross references
259 Possible Orthologues:

Neuropeptide Y Receptor Y4

Ensembl ID : ENSVPAG00000002858
Gene Symbol: NPY4R
2 Cross references
116 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSVPAG00000001871
Gene Symbol: NTRK2
1 Cross references
286 Possible Orthologues:

Nicastrin

Ensembl ID : ENSVPAG00000010618
Gene Symbol: NCSTN
1 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSVPAG00000008623
Gene Symbol: NAMPT
1 Cross references
235 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSVPAG00000000280
Gene Symbol: NFKB1
1 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).